drugset
drugset / Trial / NCT06084598

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

NCT06084598 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.

Timeline

Start
2023-10-12
Primary completion
2024-03-08
Completion
2024-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986446 Monoclonal antibody — Intravenous

Indications

No indication recorded.